MedTrace Logo

Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat

NCT01990326 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2016-02-29

No results posted yet for this study

Summary

This study will test the effects of XAF5 Gel (applied to skin each night for 6 weeks) on excess submental fat, also known as double chin. The study will also assess the safety and tolerability of XAF5 Gel.

Conditions

  • Excess Submental Fat ("Double Chin")

Interventions

DRUG

XAF5 Gel

DRUG

Placebo Gel

Sponsors & Collaborators

  • Topokine Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Michael S Singer, M.D., Ph.D. · Topokine Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01990326 on ClinicalTrials.gov